Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the
introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML …

The clinical value of serial minimal residual disease (MRD) monitoring in core binding factor
(CBF) acute myeloid leukemia (AML) by quantitative RT-PCR was prospectively assessed in …

Background Nilotinib has shown greater efficacy than imatinib in patients with newly
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …

Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid
leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have …

Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …

In the face of competing first-line treatment options for CML, early prediction of prognosis on
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …